Dietary Insights and Nutrition Support for adults on GLP-1 therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional pilot study tests the SWITCH mobile nutrition intervention in adults using GLP-1 receptor agonists for obesity and/or type 2 diabetes. Participants will do baseline assessments, use a 6-week app with daily food tracking and weekly learning modules, then complete follow-up assessments and a structured interview. The study aims to measure feasibility, acceptability, and perceived usefulness of the program. Recruitment targets adults aged 18–65 with BMI 30–49.9 or type 2 diabetes, who own smartphones and are willing to reduce caloric intake.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* • Age between 18 and 65 years.

  * BMI between 30 - 49.9 kg/m2 and/or diagnosed with type 2 diabetes.
  * Currently prescribed and using GLP-1 receptor therapy for at least 4 weeks.
  * Own a smartphone (Android or iOS) with an active data plan to support app-based intervention delivery.
  * Residing anywhere in the United States.
  * Must be willing and able to reduce caloric intake.
  * Be free of major health or psychiatric diseases, drug, or alcohol dependency.
  * Willing to sign informed consent.

Exclusion Criteria:

* • Presence of type 1 diabetes mellitus

  * Severe complications, including but not limited to proliferative retinopathy, severe peripheral neuropathy, nephropathy requiring dialysis, active foot ulcers, or recent hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state within the past 6 months.
  * Current or recent (within 6 months) participation in another structured weight loss program or clinical trial that may interfere with study outcomes.
  * Pregnancy, breastfeeding, or plans to become pregnant during the study period.
  * Current use of another investigational weight loss device or medication.
  * Diagnosed eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder) or other psychiatric conditions that may affect adherence to behavioral interventions, as determined by study staff.
  * Severe cardiovascular, hepatic, renal, or pulmonary disease that would limit participation in moderate physical activity or dietary modification.
  * Active cancer treatment (chemotherapy, radiation, or surgery) within the past 12 months.
  * Substance use disorder or alcohol dependency within the past 12 months.
  * Cognitive impairment or any medical or mental condition that would interfere with the ability to understand or comply with study procedures.
  * Lack of reliable internet or smartphone access, or unwillingness to use a mobile app for tracking and communication.

Where it's running

• University South Carolina
  Columbia, South Carolina, United States Recruiting

Study contacts

• Study coordinator: Shiba Bailey
• Email: SB25@email.sc.edu
• Phone: 8035765688

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD

  This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.

  Recruiting Hospital General Universitario Gregorio Marañon · Madrid, Madrid · NCT07658755

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.